drugset / Trial / NCT00002239

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

NCT00002239

Phase 2 Completed 68 enrolled Hoffmann-La Roche Trimeris · collab
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.

Timeline

Start
1999-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified Oral
Subject Amprenavir Other / unclassified Oral
Subject Efavirenz Other / unclassified Oral
Subject Enfuvirtide Peptide
Subject Ritonavir Other / unclassified Oral